Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study

Pediatric Blood and Cancer

Volumn 56, Issue 7, 2011, Pages 1103-1109

  Young, G ^a   Boshkov, L K ^b   Sullivan, J E ^c   Raffini, L J ^d   Cox, D S ^e   Boyle, D A ^e   Kallender, H ^e   Tarka, E A ^e   Soffer, J ^e   Hursting, M J ^f  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c University of Louisville School of Medicine   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Clinical Science Consulting   (United States)

Author keywords

Argatroban; Children; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ARGATROBAN;

ADOLESCENT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART CATHETERIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFANT; MALE; MULTICENTER STUDY; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; THROMBOSIS;

ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INFANT; LIVER FUNCTION TESTS; MALE; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 79151473713     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22852     Document Type: Article

References (33)

1. Revel-Vilk S, Chan AK. Anticoagulation therapy in children. Semin Thromb Hemost 2003; 29: 425-432.
2. Young G. Current and future antithrombotic agents in children. Expert Rev Cardiovasc Ther 2004; 2: 523-534.
3. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: A literature review. J Pediatr Hematol Oncol 2006; 28: 4-10.
4. Young G, Tarantino MD, Wohrley J, et al. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007; 5: 1654-1659.
5. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch Intern Med 2004; 164: 361-369.
6. Risch L, Fischer JE, Herklotz R, et al. Heparin-induced thrombocytopenia in paediatrics: Clinical characteristics, therapy and outcomes. Intensive Care Med 2004; 30: 1615-1624.
7. Alsoufi B, Boshkov LK, Kirby A, et al. Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: An emerging cause of morbidity and mortality. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004; 7: 155-171.
8. Klenner AF, Lubenow N, Raschke R, et al. Heparin-induced thrombocytopenia in children: 12 new cases and review of literature. Thromb Haemost 2004; 91: 719-724.
9. Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res 2006; 118: 123-135.
10. Boshkov LK, Kirby A, Shen I, et al. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg 2006; 81: S2355-S2359.
11. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 340S-380S.
12. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133: 259-269.
13. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
14. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843.
15. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856.
16. Lewis BE, Matthai WH, Jr., Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57: 177-184.
17. Matthai WH, Hursting MJ, Lewis BE, et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005; 116: 121-126.
18. Ota K, Akizawa T, Hirasawa Y, et al. Effects of argatroban as an anticoagulant for haemodialysis in patients with antithrombin III deficiency. Nephrol Dial Transplant 2003; 18: 1623-1630.
19. Potter KE, Raj A, Sullivan JE. Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support. J Pediatr Hematol Oncol 2007; 29: 265-268.
20. Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban. Pediatr Crit Care Med 2006; 7: 473-475.
21. Madabushi R, Cox DS, Hossain M, et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharm 2010, April 26 (epub ahead of print). DOI: 10.1177/0091270010365550
22. Tran JQ, DiCicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 39: 513-519.
23. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-Drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
24. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006; 129: 1407-1416.
25. Smythe MA, Stephens JL, Koerber JM, et al. A comparison of leplrudin and argatroban outcomes. Clin Appl Thromb Hemost 2005; 11: 371-374.
26. Gray A, Wallis DE, Hursting MJ, et al. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 2007; 13: 353-361.
27. Hoffman WD, Czyz Y, McCollum D, et al. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008; 42: 309-316.
28. Begelman SM, Baghdasarian SB, Singh IM, et al. Argatroban anticoagulation in intensive care patients: Effects of heart failure and multiple organ system failure. J Intensive Care Med 2008; 23: 313-320.
29. Liedel JL, Panicker N, Kahana MD. Argatroban for anticoagulation in children with heparin-induced platelet antibodies (abstract). Crit Care Med 2003; 31: A132.
30. Package Insert. Argatroban injection. Research Triangle Park, NC: GlaxoSmithKline; 2008.
31. Massicotte MP, Sofronas M, deVeber G. Difficulties in performing clinical trials of antithrombotic therapy in neonates and children. Thromb Res 2006; 188: 153-163.
32. Fenyvesi T, Harenberg J, Weiss C, et al. Comparison of two different ecarin clotting time methods. J Thromb Thrombolysis 2005; 20: 51-56.
33. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765.